Stock symbol: TSX: TOS
Outstanding shares: 47,863,402
QUEBEC CITY, Dec. 29 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that it has filed supporting technical documentation to the US Regulatory Agency and to the European Notified Body, in order to obtain clearance to export the STERIZONE(R) 125L+ Sterilizer to these markets.
The Company announced receiving Health Canada authorization to market this sterilizer in Canada on December 17, 2009. In Canada the new STERIZONE(R) 125L+ Sterilizer offers three cycles in a single sterilizer and is able to meet healthcare sterilization demands for terminal sterilization that previously required two or more low temperature sterilization systems. Engineered like other TSO3 products to be customer safe and eco-friendly, this new low temperature sterilization system also offers increased speed and instrument compatibility, high throughput and cost effective sterilization.
"We are extremely pleased that we have met the milestones of regulatory submission in multiple markets that we set out for ourselves and communicated to our investors during the year", stated Mr. R.M. (Ric) Rumble, President and CEO of TSO3. "Our new total solution in sterilization comes at a time when customers are seeking alternatives for their low temperature sterilization needs", concluded Mr. Rumble.
On December 16, 2009, TSO3 announced having entered into a global partnership with 3M, for the exclusive supply and distribution of the STERIZONE(R) 125L+ Sterilizer through 3M's operations worldwide as regulatory clearances are achieved.
TSO3 was founded in June of 1998, supported by a patented and unique technology for the sterilization of medical devices. This process uses ozone as the sterilizing agent and has been designed to allow the sterilization of heat and moisture-sensitive medical devices in healthcare settings.
The STERIZONE(R) Sterilization Process sterilizes large loads of medical devices quickly, cost-effectively, safely and in an eco-friendly way. This is in contrast to traditional gaseous low temperature sterilization methods which rely on toxic chemistry and require lengthy sterilization cycle times, or newer competitive oxidizing sterilizers which are costly to operate and limited in capability due to their load restrictions.
TSO3's first product, the STERIZONE(R) 125L Sterilizer has received clearance for commercialization from both Health Canada and the United States Food and Drug Administration (FDA), for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearances from both the Canadian and American Regulatory Agencies for sterilization of additional complex medical devices, including packaged multi-channel flexible endoscopes.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: For further information: Caroline Côté, Director, Corporate Communications and IR, Cell Phone (418) 576-2333, email@example.com; Source: TSO3 Inc.